You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

120 search results for: mechanism of disease

The <b>Disease</b> Burden <b>of</b> AD in Children and the Impact <b>of</b> Type 2 Comorbidities

expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

12 min

Dermatology

Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.

Infographic

The Role of Type 2 Inflammation in Multiple Disease Trajectories

5 min

Dermatology

How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.

The Burden <b>of</b> Atopic Dermatitis in Children – Identifying Persistent <b>Disease</b>

expert video

The Burden of Atopic Dermatitis in Children – Identifying Persistent Disease

2 min

Dermatology

Dr. Mark Koh explains how to identify children with persistent disease.

The Burden <b>of</b> Atopic Dermatitis in Children – Skin Infections and More Severe <b>Disease</b>

expert video

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease

1 min

Dermatology

Dr. Mark Koh talks about skin infections and their impact on disease severity.

Differences in Manifestations <b>of</b> Type 2 Inflammatory <b>Disease</b>s

expert video

Differences in Manifestations of Type 2 Inflammatory Diseases

2 min

Dermatology

Dr. Brian Kim highlights the differences in manifestation of type 2 inflammatory diseases.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

interactivity

COPD and Asthma: What's the Difference and Is There a Link?

5 min

Pulmonology

Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

Impact <b>of</b> Advanced Systemic Therapies on <b>Disease</b> Control in AD

expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

6 min

Dermatology

Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.

How do You Define Active <b>Disease</b> (CRSwNP) When Looking at the Nose With an Endoscope?

expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

2 min

Rhinology

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.

Atopic Dermatitis (AD) is a Type 2 Inflammatory <b>Disease</b>

videoanimation

Atopic Dermatitis (AD) is a Type 2 Inflammatory Disease

2 min

Dermatology

Discover the pathophysiological mechanisms involved in atopic dermatitis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BahrainChange country/region